5JE.F BACTIGUARD HLDG B
- Market cap
- EUR 44.3M
- P/E
- 62.0x
- P/B
- 1.55x
- ROE
- -2.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 5JE.F undervalued?
Graham number5JE.F trades 106.7% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
BACTIGUARD HLDG B fundamental analysis
No fundamental analysis for BACTIGUARD HLDG B yet.
BACTIGUARD HLDG B stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About BACTIGUARD HLDG B
Bactiguard Holding AB (publ), a medTech company, provides infection prevention technology and solutions in orthopedics, cardiology, neurology, urology, and vascular access areas. The company also has a portfolio of wound management products, such as Hydrocyn Aqua, an antimicrobial solution and gel for acute, chronic, and infected wounds; and surgical sutures comprising non-absorbable, natural absorbable, synthetic absorable, and specialty sutures. It also operates through li…
Full company profileBACTIGUARD HLDG B financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
BACTIGUARD HLDG B annual financial statements (SEK; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 227M | 204M | 242M | 216M | 202M |
| Gross Profit | 183M | 140M | 206M | 185M | 178M |
| Operating Income | -54.2M | -137M | -38.2M | -7.53M | -11.5M |
| EBITDA | -1.92M | -77.8M | 25.0M | 41.6M | 36.6M |
| Net Income | -52.9M | -138M | -29.8M | -7.84M | -8.66M |
| EPS | -1.51 | -3.95 | -0.85 | -0.22 | -0.25 |
| Balance Sheet | |||||
| Total Assets | 808M | 662M | 656M | 545M | 524M |
| Total Liabilities | 312M | 309M | 328M | 230M | 211M |
| Shareholders' Equity | 496M | 353M | 328M | 315M | 313M |
| Cash & Short-term Investments | 198M | 123M | 117M | 44.3M | 55.1M |
| Cash Flow | |||||
| Operating Cash Flow | 3.06M | -52.3M | 25.0M | -1.49M | 25.3M |
| Capital Expenditure | 10.9M | 8.61M | 14.8M | 5.72M | 2.29M |
| Free Cash Flow | -7.86M | -60.9M | 10.2M | -7.21M | 23.0M |
| Ratios | |||||
| ROE | -10.7% | -39.2% | -9.1% | -2.5% | -2.8% |
| ROA | -6.5% | -20.9% | -4.5% | -1.4% | -1.7% |
| Net Profit Margin | -23.3% | -67.8% | -12.3% | -3.6% | -4.3% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
BACTIGUARD HLDG B dividends
BACTIGUARD HLDG B has not paid dividends in the last 4 fiscal years.
Who owns BACTIGUARD HLDG B
- Insiders 37.56%
- Institutions 37.19%
- Public & others 25.25%
- Shares outstanding 31.0M
- Free float 13.2M
BACTIGUARD HLDG B company profile
- Company name
- BACTIGUARD HLDG B
- Ticker
- 5JE.F
- ISIN
- SE0005878741
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 166
- Fiscal year end
- December
- Address
- Vasagatan 11, Stockholm, Sweden, 111 20
- Phone
- 46 84 40 58 80
- Website
- bactiguard.com
About BACTIGUARD HLDG B
Bactiguard Holding AB (publ), a medTech company, provides infection prevention technology and solutions in orthopedics, cardiology, neurology, urology, and vascular access areas. The company also has a portfolio of wound management products, such as Hydrocyn Aqua, an antimicrobial solution and gel for acute, chronic, and infected wounds; and surgical sutures comprising non-absorbable, natural absorbable, synthetic absorable, and specialty sutures. It also operates through license partnerships with global MedTech companies that apply the technology to medical devices and sell them under own brand and co-branded. The company has licensed partnership with Becton, Dickinson & Company for urinary catheter bardex IC and lubrisil IC; Well Lead Medical for catheters and tubes; and Zimmer Biomet for orthopedic trauma implants. It operates in the United States, Sweden, Malaysia, India, Bangladesh, Indonesia, the Kingdom of Saudi Arabia, and internationally. The company was founded in 2005 and is headquartered in Stockholm, Sweden.
BACTIGUARD HLDG B management
8- Ms. Christine LindChief Executive Officer · born 1974
- Mr. Patrick Fruergaard BachChief Financial Officer · born 1983
- Dr. Nathaniel Bachrach Ph.D.Chief Scientific Officer · born 1966
- Ms. Kajsa BjorklundExecutive VP of Research & Development · born 1973
- Ms. Sophie DahanExecutive Vice President of Business Development & Alliance Management · born 1965
- Mr. Ian S. E. N. ChristensenSenior Vice President of Wound Management · born 1973
- Mr. Alf LaurellExecutive Vice President of Regulatory & Quality · born 1981
- Clément BègueEVP Data & Intelligence · born 1986